(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
@ $23.28
发出时间: 14 Feb 2024 @ 22:30
回报率: 5.33%
上一信号: Feb 13 - 22:30
上一信号:
回报率: 0.28 %
Live Chart Being Loaded With Signals
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States...
Stats | |
---|---|
今日成交量 | 1.68M |
平均成交量 | 1.10M |
市值 | 2.54B |
EPS | $0 ( 2024-05-01 ) |
下一个收益日期 | ( $0.220 ) 2024-05-17 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 26.09 |
ATR14 | $0.0380 (0.15%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-01 | Swisher Daniel N Jr | Sell | 2 200 | Stock option (right to buy) |
2024-05-01 | Swisher Daniel N Jr | Buy | 2 200 | Common Stock |
2024-05-01 | Swisher Daniel N Jr | Sell | 2 200 | Common Stock |
2024-04-10 | Mahoney David L | Buy | 27 806 | Common Stock |
2024-04-10 | Mahoney David L | Buy | 30 000 | Common Stock |
INSIDER POWER |
---|
61.98 |
Last 97 transactions |
Buy: 1 926 069 | Sell: 453 397 |
音量 相关性
Corcept Therapeutics Inc 相关性
10 最正相关 | |
---|---|
GOODM | 0.945 |
SVAC | 0.941 |
PAIC | 0.916 |
TLGT | 0.913 |
ALVR | 0.898 |
GETVV | 0.897 |
RMRM | 0.897 |
SVOK | 0.891 |
BNDX | 0.889 |
MTSL | 0.888 |
10 最负相关 | |
---|---|
AMRB | -0.968 |
NETE | -0.941 |
MMAC | -0.919 |
PFG | -0.901 |
LINC | -0.887 |
FFBW | -0.872 |
SRAC | -0.871 |
REG | -0.865 |
IOSP | -0.865 |
NOVT | -0.861 |
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Corcept Therapeutics Inc 相关性 - 货币/商品
Corcept Therapeutics Inc 财务报表
Annual | 2023 |
营收: | $482.38M |
毛利润: | $475.89M (98.66 %) |
EPS: | $1.020 |
FY | 2023 |
营收: | $482.38M |
毛利润: | $475.89M (98.66 %) |
EPS: | $1.020 |
FY | 2022 |
营收: | $401.86M |
毛利润: | $396.47M (98.66 %) |
EPS: | $0.950 |
FY | 2021 |
营收: | $365.98M |
毛利润: | $360.70M (98.56 %) |
EPS: | $0.970 |
Financial Reports:
No articles found.
Corcept Therapeutics Inc
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。